Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$49.84 - $70.47 $3.38 Million - $4.78 Million
-67,800 Reduced 43.71%
87,300 $5.53 Million
Q2 2024

Aug 14, 2024

BUY
$47.39 - $80.2 $1.22 Million - $2.07 Million
25,800 Added 19.95%
155,100 $8.22 Million
Q1 2024

May 15, 2024

BUY
$17.4 - $94.5 $2.25 Million - $12.2 Million
129,300 New
129,300 $10.6 Million
Q3 2023

Nov 14, 2023

SELL
$10.92 - $16.0 $2.08 Million - $3.05 Million
-190,800 Reduced 94.93%
10,200 $112,000
Q2 2023

Aug 14, 2023

BUY
$14.84 - $24.79 $2.98 Million - $4.98 Million
201,000 New
201,000 $3.26 Million

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.95B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.